{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T17:50:34Z","timestamp":1790617834352,"version":"4.1.0"},"reference-count":113,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2025,5,22]],"date-time":"2025-05-22T00:00:00Z","timestamp":1747872000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biomolecules"],"abstract":"<jats:p>Prostate cancer, a slow-growing tumor, develops through the over-proliferation of malignant cells in the prostate and is one of the most common types of cancer. Active surveillance, radical prostatectomy, external beam radiation, brachytherapy, cryotherapy, stereotactic body radiation therapy, hormone therapy, and chemotherapy are common treatment strategies for prostate cancer. However, resistance to treatment in advanced prostate cancer is a concerning issue in the use of these therapies. Immune checkpoint inhibitor (ICI) therapy for prostate cancer is an emerging strategy for the treatment of advanced prostate cancers but the resistance and limited efficacy to ICIs observed in metastatic castration-resistant prostate cancer (mCRPC) raises concerns. The ongoing clinical trials for combination therapies for mCRPC have provided some hope. This review concisely discusses the molecular and cellular mechanisms, immunotherapy, the limitations of ICIs, combination therapies, and the prospects of developing novel therapeutics for prostate cancer.<\/jats:p>","DOI":"10.3390\/biom15060751","type":"journal-article","created":{"date-parts":[[2025,5,22]],"date-time":"2025-05-22T04:32:37Z","timestamp":1747888357000},"page":"751","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Immune Checkpoint Inhibitor Therapy for Prostate Cancer: Present and Future Prospectives"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6286-2341","authenticated-orcid":false,"given":"Vikrant","family":"Rai","sequence":"first","affiliation":[{"name":"Department of Translational Research, Western University of Health Sciences, Pomona, CA 91762, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,5,22]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1097\/JU.0000000000003452","article-title":"Updates to Advanced Prostate Cancer: AUA\/SUO Guideline (2023)","volume":"209","author":"Lowrance","year":"2023","journal-title":"J. Urol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/j.euo.2021.09.006","article-title":"Epidemiology and Prevention of Prostate Cancer","volume":"4","author":"Gandaglia","year":"2021","journal-title":"Eur. Urol. Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"63","DOI":"10.14740\/wjon1191","article-title":"Epidemiology of Prostate Cancer","volume":"10","author":"Rawla","year":"2019","journal-title":"World J. Oncol."},{"key":"ref_4","first-page":"S3","article-title":"Risk factors for prostate cancer","volume":"4","author":"Gann","year":"2002","journal-title":"Rev. Urol."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Cicione, A., Brassetti, A., Lombardo, R., Franco, A., Turchi, B., D\u2019Annunzio, S., Nacchia, A., Tubaro, A., Simone, G., and De Nunzio, C. (2022). Metabolic Syndrome and Physical Inactivity May Be Shared Etiological Agents of Prostate Cancer and Coronary Heart Diseases. Cancers, 14.","DOI":"10.3390\/cancers14040936"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.soncn.2011.07.002","article-title":"Prostate cancer overview","volume":"27","author":"Dunn","year":"2011","journal-title":"Semin. Oncol. Nurs."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2532","DOI":"10.1001\/jama.2017.7248","article-title":"The diagnosis and treatment of prostate cancer: A review","volume":"317","author":"Litwin","year":"2017","journal-title":"Jama"},{"key":"ref_8","unstructured":"Board, P.A.T.E. (2024). Prostate cancer treatment (PDQ\u00ae). PDQ Cancer Information Summaries [Internet], National Cancer Institute (US)."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/s41391-021-00394-5","article-title":"Advances in PSMA-targeted therapy for prostate cancer","volume":"25","author":"Wang","year":"2022","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1038\/s41391-022-00640-4","article-title":"Cardiovascular adverse events-related to GnRH agonists and GnRH antagonists: Analysis of real-life data from Eudra-Vigilance and Food and Drug Administration databases entries","volume":"26","author":"Cicione","year":"2023","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"JCO2401283","DOI":"10.1200\/JCO-24-01283","article-title":"Pembrolizumab Plus Docetaxel Versus Docetaxel for Previously Treated Metastatic Castration-Resistant Prostate Cancer: The Randomized, Double-Blind, Phase III KEYNOTE-921 Trial","volume":"43","author":"Petrylak","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Onishi, K., Nakai, Y., Tachibana, A., Nishimura, N., Maesaka, F., Tomizawa, M., Morizawa, Y., Hori, S., Gotoh, D., and Miyake, M. (2025). Testosterone Recovery and Quality of Life of Japanese Patients After Short-Term Neoadjuvant Androgen Deprivation Therapy With Low-Dose-Rate Brachytherapy for Prostate Cancer. Int. J. Urol.","DOI":"10.1111\/iju.70018"},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Strasner, A., and Karin, M. (2015). Immune Infiltration and Prostate Cancer. Front. Oncol., 5.","DOI":"10.3389\/fonc.2015.00128"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"694","DOI":"10.37349\/etat.2022.00108","article-title":"The tumor innate immune microenvironment in prostate cancer: An overview of soluble factors and cellular effectors","volume":"3","author":"Palano","year":"2022","journal-title":"Explor. Target. Anti-Tumor Ther."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.zefq.2021.12.008","article-title":"[Cross-regional telemedicine services as a supplement to rural primary care: A mixed-methods analysis]","volume":"169","author":"Harder","year":"2022","journal-title":"Z. Evidenz Fortbild. Qual. Gesundheitswesen"},{"key":"ref_16","first-page":"941","article-title":"Tumour-stroma interactions between metastatic prostate cancer cells and fibroblasts","volume":"18","author":"Kaminski","year":"2006","journal-title":"Int. J. Mol. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1038\/s41391-021-00340-5","article-title":"How to turn up the heat on the cold immune microenvironment of metastatic prostate cancer","volume":"24","author":"Stultz","year":"2021","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.ajur.2016.08.002","article-title":"Immune phenotypes of prostate cancer cells: Evidence of epithelial immune cell-like transition?","volume":"3","author":"Lin","year":"2016","journal-title":"Asian J. Urol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"119132","DOI":"10.1016\/j.lfs.2021.119132","article-title":"The role of regulatory T cells in the pathogenesis and treatment of prostate cancer","volume":"284","author":"Karpisheh","year":"2021","journal-title":"Life Sci."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Testa, U., Castelli, G., and Pelosi, E. (2019). Cellular and Molecular Mechanisms Underlying Prostate Cancer Development: Therapeutic Implications. Medicines, 6.","DOI":"10.3390\/medicines6030082"},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Maekawa, S., Takata, R., and Obara, W. (2024). Molecular Mechanisms of Prostate Cancer Development in the Precision Medicine Era: A Comprehensive Review. Cancers, 16.","DOI":"10.3390\/cancers16030523"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"215619","DOI":"10.1016\/j.canlet.2022.215619","article-title":"Molecular mechanisms and genetic alterations in prostate cancer: From diagnosis to targeted therapy","volume":"534","author":"Fontana","year":"2022","journal-title":"Cancer Lett."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"7217","DOI":"10.18632\/oncotarget.2406","article-title":"Molecular pathways and targets in prostate cancer","volume":"5","author":"Shtivelman","year":"2014","journal-title":"Oncotarget"},{"key":"ref_24","first-page":"168","article-title":"Molecular alterations associated with prostate cancer","volume":"71","author":"Perdomo","year":"2018","journal-title":"Cent. Eur. J. Urol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"3417","DOI":"10.1158\/0008-5472.CAN-16-1616","article-title":"Novel Androgen Receptor Coregulator GRHL2 Exerts Both Oncogenic and Antimetastatic Functions in Prostate Cancer","volume":"77","author":"Paltoglou","year":"2017","journal-title":"Cancer Res."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/s12943-024-01994-0","article-title":"Co-transcriptional R-loops-mediated epigenetic regulation drives growth retardation and docetaxel chemosensitivity enhancement in advanced prostate cancer","volume":"23","author":"Ying","year":"2024","journal-title":"Mol. Cancer"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"6503","DOI":"10.1158\/0008-5472.CAN-11-0532","article-title":"Intratumoral de novo steroid synthesis activates androgen receptor in castration-resistant prostate cancer and is upregulated by treatment with CYP17A1 inhibitors","volume":"71","author":"Cai","year":"2011","journal-title":"Cancer Res."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1007\/s00018-005-5471-y","article-title":"Unfaithfulness and promiscuity of a mutant androgen receptor in a hormone-refractory prostate cancer","volume":"63","author":"Monge","year":"2006","journal-title":"Cell. Mol. Life Sci."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/aps.2014.18","article-title":"Androgen receptor: Structure, role in prostate cancer and drug discovery","volume":"36","author":"Tan","year":"2015","journal-title":"Acta Pharmacol. Sin."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"R143","DOI":"10.1530\/ERC-22-0140","article-title":"Androgen receptor mutations for precision medicine in prostate cancer","volume":"29","author":"Shiota","year":"2022","journal-title":"Endocr. Relat. Cancer"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1093\/molehr\/gag064","article-title":"Molecular biology of prostate cancer","volume":"9","author":"Schulz","year":"2003","journal-title":"Mol. Hum. Reprod."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1097\/01.ju.0000143195.49685.ce","article-title":"Association between cancer-free survival and telomere DNA content in prostate tumors","volume":"173","author":"Fordyce","year":"2005","journal-title":"J. Urol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1158\/2159-8290.CD-13-0135","article-title":"Prostate cancer cell telomere length variability and stromal cell telomere length as prognostic markers for metastasis and death","volume":"3","author":"Heaphy","year":"2013","journal-title":"Cancer Discov."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/j.eururo.2011.06.035","article-title":"Epigenetics in prostate cancer: Biologic and clinical relevance","volume":"60","author":"Jeronimo","year":"2011","journal-title":"Eur. Urol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.urolonc.2023.03.005","article-title":"Epigenetics regulation of prostate cancer: Biomarker and therapeutic potential","volume":"41","author":"Ragavi","year":"2023","journal-title":"Urol. Oncol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"6764","DOI":"10.1158\/1078-0432.CCR-17-0019","article-title":"Immunotherapy of Prostate Cancer: Facts and Hopes","volume":"23","author":"Bilusic","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1002\/pros.23955","article-title":"Extreme responses to immune checkpoint blockade following bipolar androgen therapy and enzalutamide in patients with metastatic castration resistant prostate cancer","volume":"80","author":"Markowski","year":"2020","journal-title":"Prostate"},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Venkatachalam, S., McFarland, T.R., Agarwal, N., and Swami, U. (2021). Immune Checkpoint Inhibitors in Prostate Cancer. Cancers, 13.","DOI":"10.3390\/cancers13092187"},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Adamaki, M., and Zoumpourlis, V. (2021). Immunotherapy as a Precision Medicine Tool for the Treatment of Prostate Cancer. Cancers, 13.","DOI":"10.3390\/cancers13020173"},{"key":"ref_40","first-page":"210","article-title":"Prostate cancer immunotherapy: A review of recent advancements with novel treatment methods and efficacy","volume":"10","author":"Wang","year":"2022","journal-title":"Am. J. Clin. Exp. Urol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.ucl.2020.07.008","article-title":"Immunotherapy for Localized Prostate Cancer: The Next Frontier?","volume":"47","author":"Patel","year":"2020","journal-title":"Urol. Clin. N. Am."},{"key":"ref_42","first-page":"503","article-title":"Ipilimumab (yervoy) prolongs survival in advanced melanoma: Serious side effects and a hefty price tag may limit its use","volume":"37","author":"Fellner","year":"2012","journal-title":"Pharm. Ther."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"3","DOI":"10.4111\/icu.20210369","article-title":"Immunotherapy for prostate cancer: Requirements for a successful regime transfer","volume":"63","author":"Jeong","year":"2022","journal-title":"Investig. Clin. Urol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"3155","DOI":"10.1007\/s00262-021-02915-6","article-title":"Inhibition of STAT3 augments antitumor efficacy of anti-CTLA-4 treatment against prostate cancer","volume":"70","author":"Witt","year":"2021","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"3015","DOI":"10.1084\/jem.20090847","article-title":"PD-L1 regulates the development, maintenance, and function of induced regulatory T cells","volume":"206","author":"Francisco","year":"2009","journal-title":"J. Exp. Med."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1093\/annonc\/mdy232","article-title":"Pembrolizumab for advanced prostate adenocarcinoma: Findings of the KEYNOTE-028 study","volume":"29","author":"Hansen","year":"2018","journal-title":"Ann. Oncol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1200\/JCO.19.01638","article-title":"Pembrolizumab for Treatment-Refractory Metastatic Castration-Resistant Prostate Cancer: Multicohort, Open-Label Phase II KEYNOTE-199 Study","volume":"38","author":"Antonarakis","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"3753","DOI":"10.1158\/1078-0432.CCR-18-4070","article-title":"FDA Approval Summary: Pembrolizumab for the Treatment of Microsatellite Instability-High Solid Tumors","volume":"25","author":"Marcus","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"3360","DOI":"10.1158\/1078-0432.CCR-20-1981","article-title":"Safety and Clinical Activity of Atezolizumab in Patients with Metastatic Castration-Resistant Prostate Cancer: A Phase I Study","volume":"27","author":"Petrylak","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"TPS5090","DOI":"10.1158\/1538-7445.AM2020-CT014","article-title":"IMbassador250: A phase III trial comparing atezolizumab with enzalutamide vs enzalutamide alone in patients with metastatic castration-resistant prostate cancer (mCRPC)","volume":"80","author":"Sweeney","year":"2020","journal-title":"Cancer Res."},{"key":"ref_51","first-page":"e368","article-title":"PD16-12 pembrolizumab plus enzalutamide in abiraterone-pretreated patients with metastatic castration-resistant prostate cancer: Updated results from KEYNOTE-365 cohort C","volume":"203","author":"Fong","year":"2020","journal-title":"J. Urol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"5543","DOI":"10.1200\/JCO.2020.38.15_suppl.5543","article-title":"KEYNOTE-199 cohorts (C) 4 and 5: Phase II study of pembrolizumab (pembro) plus enzalutamide (enza) for enza-resistant metastatic castration-resistant prostate cancer (mCRPC)","volume":"38","author":"Hoimes","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/nrd.2017.243","article-title":"mRNA vaccines\u2014A new era in vaccinology","volume":"17","author":"Pardi","year":"2018","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Buonaguro, L., and Tagliamonte, M. (2023). Peptide-based vaccine for cancer therapies. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1210044"},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Stephens, A.J., Burgess-Brown, N.A., and Jiang, S. (2021). Beyond Just Peptide Antigens: The Complex World of Peptide-Based Cancer Vaccines. Front. Immunol., 12.","DOI":"10.3389\/fimmu.2021.696791"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.4161\/hv.20988","article-title":"Personalized peptide vaccination: A novel immunotherapeutic approach for advanced cancer","volume":"8","author":"Sasada","year":"2012","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"4246","DOI":"10.3390\/curroncol30040323","article-title":"Metastatic Castration-Resistant Prostate Cancer, Immune Checkpoint Inhibitors, and Beyond","volume":"30","author":"Lanka","year":"2023","journal-title":"Curr. Oncol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1186\/s40425-018-0463-2","article-title":"Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and without DNA damage repair mutations","volume":"6","author":"Karzai","year":"2018","journal-title":"J. Immunother. Cancer"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1200\/JCO.2020.38.6_suppl.100","article-title":"KEYNOTE-365 cohort A updated results: Pembrolizumab (pembro) plus olaparib in docetaxel-pretreated patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)","volume":"38","author":"Yu","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1200\/JCO.2020.38.6_suppl.103","article-title":"KEYNOTE-365 cohort B updated results: Pembrolizumab (pembro) plus docetaxel and prednisone in abiraterone (abi) or enzalutamide (enza)-pretreated patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC)","volume":"38","author":"Kolinsky","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"5565","DOI":"10.1200\/JCO.2020.38.15_suppl.5565","article-title":"Safety and clinical activity of atezolizumab (atezo)+ radium-223 dichloride (r-223) in 2L metastatic castration-resistant prostate cancer (mCRPC): Results from a phase Ib clinical trial","volume":"38","author":"Morris","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1093\/annonc\/mdt107","article-title":"Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: Results from an open-label, multicenter phase I\/II study","volume":"24","author":"Slovin","year":"2013","journal-title":"Ann. Oncol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/S1470-2045(14)70189-5","article-title":"Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): A multicentre, randomised, double-blind, phase 3 trial","volume":"15","author":"Kwon","year":"2014","journal-title":"Lancet Oncol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1016\/j.eururo.2020.07.032","article-title":"Final Analysis of the Ipilimumab Versus Placebo Following Radiotherapy Phase III Trial in Postdocetaxel Metastatic Castration-resistant Prostate Cancer Identifies an Excess of Long-term Survivors","volume":"78","author":"Fizazi","year":"2020","journal-title":"Eur. Urol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1038\/s41391-019-0176-8","article-title":"A pilot trial of pembrolizumab plus prostatic cryotherapy for men with newly diagnosed oligometastatic hormone-sensitive prostate cancer","volume":"23","author":"Ross","year":"2020","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"e17564","DOI":"10.1200\/JCO.2020.38.15_suppl.e17564","article-title":"Phase Ib study assessing different sequencing regimens of atezolizumab (anti-PD-L1) and sipuleucel-T (SipT) in patients who have asymptomatic or minimally symptomatic metastatic castrate resistant prostate cancer","volume":"38","author":"Rosser","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"S543","DOI":"10.1016\/j.annonc.2020.08.2076","article-title":"682P Results from ADVANCE: A phase I\/II open-label non-randomised safety and efficacy study of the viral vectored ChAdOx1-MVA 5T4 (VTP-800) vaccine in combination with PD-1 checkpoint blockade in metastatic prostate cancer","volume":"31","author":"Tuthill","year":"2020","journal-title":"Ann. Oncol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/S1470-2045(12)70006-2","article-title":"Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: A phase 1 dose-escalation trial","volume":"13","author":"Madan","year":"2012","journal-title":"Lancet Oncol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"28561","DOI":"10.18632\/oncotarget.25564","article-title":"Ipilimumab plus nivolumab and DNA-repair defects in AR-V7-expressing metastatic prostate cancer","volume":"9","author":"Boudadi","year":"2018","journal-title":"Oncotarget"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.ccell.2020.08.007","article-title":"Nivolumab Plus Ipilimumab for Metastatic Castration-Resistant Prostate Cancer: Preliminary Analysis of Patients in the CheckMate 650 Trial","volume":"38","author":"Sharma","year":"2020","journal-title":"Cancer Cell"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"v885","DOI":"10.1093\/annonc\/mdz394.044","article-title":"CCTG IND 232: A phase II study of durvalumab with or without tremelimumab in patients with metastatic castration resistant prostate cancer (mCRPC)","volume":"30","author":"Hotte","year":"2019","journal-title":"Ann. Oncol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"e002919","DOI":"10.1136\/jitc-2021-002919","article-title":"Combined CTLA-4 and PD-L1 blockade in patients with chemotherapy-naive metastatic castration-resistant prostate cancer is associated with increased myeloid and neutrophil immune subsets in the bone microenvironment","volume":"9","author":"Subudhi","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"5564","DOI":"10.1200\/JCO.2020.38.15_suppl.5564","article-title":"Cabozantinib in combination with atezolizumab in patients with metastatic castration-resistant prostate cancer: Results of cohort 6 of the COSMIC-021 study","volume":"38","author":"Agarwal","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"17588359241269676","DOI":"10.1177\/17588359241269676","article-title":"Promising therapy for neuroendocrine prostate cancer: Current status and future directions","volume":"16","author":"Fei","year":"2024","journal-title":"Ther. Adv. Med. Oncol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1200\/JCO.2025.43.5_suppl.217","article-title":"Lewis Y antigen as a novel target for CAR (chimeric antigen receptor) T-cell therapy in patients with neuroendocrine prostate cancer","volume":"43","author":"Kulakowska","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1002\/pros.24189","article-title":"Chemotherapy with atezolizumab for small cell or neuroendocrine carcinoma of the prostate: A single institution experience","volume":"81","author":"Wee","year":"2021","journal-title":"Prostate"},{"key":"ref_77","first-page":"1","article-title":"Pembrolizumab for platinum refractory small cell carcinoma of the prostate: Case report","volume":"3","author":"Salhab","year":"2018","journal-title":"Hematol. Med. Oncol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"eaav0891","DOI":"10.1126\/scitranslmed.aav0891","article-title":"Delta-like protein 3 expression and therapeutic targeting in neuroendocrine prostate cancer","volume":"11","author":"Puca","year":"2019","journal-title":"Sci. Transl. Med."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"e505","DOI":"10.1002\/ctm2.505","article-title":"Survival of castration-resistant prostate cancer patients treated with dendritic-tumor cell hybridomas is negatively correlated with changes in peripheral blood CD56(bright) CD16(-) natural killer cells","volume":"11","author":"Hawlina","year":"2021","journal-title":"Clin. Transl. Med."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"102941","DOI":"10.1016\/j.ctrv.2025.102941","article-title":"Current and future directions in theranostics for neuroendocrine prostate cancer","volume":"136","author":"Bilgin","year":"2025","journal-title":"Cancer Treat. Rev."},{"key":"ref_81","doi-asserted-by":"crossref","unstructured":"Bernal, A., Bechler, A.J., Mohan, K., Rizzino, A., and Mathew, G. (2024). The Current Therapeutic Landscape for Metastatic Prostate Cancer. Pharmaceuticals, 17.","DOI":"10.3390\/ph17030351"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"104604","DOI":"10.1016\/j.critrevonc.2024.104604","article-title":"Synergistic effects of immunotherapy and adjunctive therapies in prostate cancer management","volume":"207","author":"Chen","year":"2024","journal-title":"Crit. Rev. Oncol.\/Hematol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1038\/nature09744","article-title":"The genomic complexity of primary human prostate cancer","volume":"470","author":"Berger","year":"2011","journal-title":"Nature"},{"key":"ref_84","unstructured":"Hua, L., Xia, H., and Zheng, W. (2020). The Association between Immune Infiltration and Clinical Phenotypes and Prognosis of Prostate Cancer. Iran. J. Biotechnol., 18."},{"key":"ref_85","doi-asserted-by":"crossref","unstructured":"Niu, W., Zhang, T., and Ma, L. (2023). Correlation analysis between immune-related genes and cell infiltration revealed prostate cancer immunotherapy biomarkers linked to T cells gamma delta. Sci. Rep., 13.","DOI":"10.1038\/s41598-023-28475-6"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"5137","DOI":"10.1172\/JCI96268","article-title":"Targeted hypoxia reduction restores T cell infiltration and sensitizes prostate cancer to immunotherapy","volume":"128","author":"Jayaprakash","year":"2018","journal-title":"J. Clin. Investig."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1038\/s41416-019-0542-2","article-title":"Acidity promotes tumour progression by altering macrophage phenotype in prostate cancer","volume":"121","author":"Gatenbee","year":"2019","journal-title":"Br. J. Cancer"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"234","DOI":"10.18632\/oncotarget.2703","article-title":"PD-L1 is highly expressed in Enzalutamide resistant prostate cancer","volume":"6","author":"Bishop","year":"2015","journal-title":"Oncotarget"},{"key":"ref_89","doi-asserted-by":"crossref","unstructured":"Zhou, X., Ni, Y., Liang, X., Lin, Y., An, B., He, X., and Zhao, X. (2022). Mechanisms of tumor resistance to immune checkpoint blockade and combination strategies to overcome resistance. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.915094"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/s13045-019-0770-1","article-title":"Cancer-associated fibroblasts: An emerging target of anti-cancer immunotherapy","volume":"12","author":"Liu","year":"2019","journal-title":"J. Hematol. Oncol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"e2848","DOI":"10.1038\/cddis.2017.225","article-title":"Human cancer-associated fibroblasts enhance glutathione levels and antagonize drug-induced prostate cancer cell death","volume":"8","author":"Cheteh","year":"2017","journal-title":"Cell Death Dis."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"4159","DOI":"10.1093\/bioinformatics\/btz193","article-title":"ScanNeo: Identifying indel-derived neoantigens using RNA-Seq data","volume":"35","author":"Wang","year":"2019","journal-title":"Bioinformatics"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"5769","DOI":"10.3390\/curroncol30060432","article-title":"Immunotherapy in Prostate Cancer: State of Art and New Therapeutic Perspectives","volume":"30","author":"Maselli","year":"2023","journal-title":"Curr. Oncol."},{"key":"ref_94","doi-asserted-by":"crossref","unstructured":"Li, T., Qian, X., Liu, J., Xue, F., Luo, J., Yao, G., Yan, J., Liu, X., Xiao, B., and Li, J. (2023). Radiotherapy plus immune checkpoint inhibitor in prostate cancer. Front. Oncol., 13.","DOI":"10.3389\/fonc.2023.1210673"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"14","DOI":"10.22465\/juo.234600100005","article-title":"Current update on prostate cancer immunotherapy","volume":"21","author":"Kim","year":"2023","journal-title":"Korean J. Urol. Oncol."},{"key":"ref_96","doi-asserted-by":"crossref","unstructured":"Lampe, H., Tam, L., and Hansen, A.R. (2024). Bi-specific T-cell engagers (BiTEs) in prostate cancer and strategies to enhance development: Hope for a BiTE-r future. Front. Pharmacol., 15.","DOI":"10.3389\/fphar.2024.1399802"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1016\/S1470-2045(23)00451-5","article-title":"Single-dose (177)Lu-PSMA-617 followed by maintenance pembrolizumab in patients with metastatic castration-resistant prostate cancer: An open-label, dose-expansion, phase 1 trial","volume":"24","author":"Aggarwal","year":"2023","journal-title":"Lancet Oncol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.bbrc.2023.09.018","article-title":"F77 antigen is a promising target for adoptive T cell therapy of prostate cancer","volume":"680","author":"Grover","year":"2023","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/s11302-012-9350-3","article-title":"A2B adenosine receptor blockade inhibits growth of prostate cancer cells","volume":"9","author":"Wei","year":"2013","journal-title":"Purinergic Signal"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"TPS271","DOI":"10.1200\/JCO.2023.41.6_suppl.TPS271","article-title":"Evolution: Phase II study of radionuclide 177Lu-PSMA-617 therapy versus 177Lu-PSMA-617 in combination with ipilimumab and nivolumab for men with metastatic castration-resistant prostate cancer (mCRPC; ANZUP 2001)","volume":"41","author":"Sandhu","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_101","doi-asserted-by":"crossref","unstructured":"Huang, L., Xie, Y., Jiang, S., Dai, T., Xu, Z., and Shan, H. (2024). Insights into immune microenvironment and therapeutic targeting in androgen-associated prostate cancer subtypes. Sci. Rep., 14.","DOI":"10.1038\/s41598-024-68863-0"},{"key":"ref_102","doi-asserted-by":"crossref","unstructured":"Meng, L., Yang, Y., Mortazavi, A., and Zhang, J. (2023). Emerging Immunotherapy Approaches for Treating Prostate Cancer. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms241814347"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/j.trecan.2024.05.003","article-title":"B7-H3: A robust target for immunotherapy in prostate cancer","volume":"10","author":"Pulido","year":"2024","journal-title":"Trends Cancer"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1038\/s41420-023-01453-7","article-title":"B7-H3 specific CAR-T cells exhibit potent activity against prostate cancer","volume":"9","author":"Li","year":"2023","journal-title":"Cell Death Discov."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"7331","DOI":"10.1158\/1078-0432.CCR-18-4121","article-title":"Phase I Study of the Novel Enhancer of Zeste Homolog 2 (EZH2) Inhibitor GSK2816126 in Patients with Advanced Hematologic and Solid Tumors","volume":"25","author":"Yap","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1002\/cam4.5028","article-title":"Study on pharmacokinetic interactions between SHR2554 and itraconazole in healthy subjects: A single-center, open-label phase I trial","volume":"12","author":"Deng","year":"2023","journal-title":"Cancer Med."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1158\/2326-6066.CIR-22-0306","article-title":"Randomized Phase II Study Evaluating the Addition of Pembrolizumab to Radium-223 in Metastatic Castration-resistant Prostate Cancer","volume":"12","author":"Choudhury","year":"2024","journal-title":"Cancer Immunol. Res."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1200\/JCO.2024.42.4_suppl.18","article-title":"CONTACT-02: Phase 3 study of cabozantinib (C) plus atezolizumab (A) vs second novel hormonal therapy (NHT) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)","volume":"42","author":"Agarwal","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_109","doi-asserted-by":"crossref","unstructured":"Fan, Z., Oh, D.Y., Wong, A., Shinohara, K., Nguyen, H., Hwang, C., Chang, H., Starzinski, A., Li, T., and De Leon, C. (2023). 862 TLR9 agonism promotes cytotoxic T cell persistence and myeloid remodeling when combined with radiation therapy and PD-1 blockade in oligometastatic prostate cancer patients. J. ImmunoTher. Cancer, 11.","DOI":"10.1136\/jitc-2023-SITC2023.0862"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"5013","DOI":"10.1200\/JCO.2024.42.16_suppl.5013","article-title":"Nivolumab and ipilimumab for metastatic prostate cancer with an immunogenic signature: The NEPTUNES multi-centre two-cohort, biomarker-selected phase 2 trial","volume":"42","author":"Linch","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1200\/JCO.2023.41.6_suppl.22","article-title":"Nivolumab plus ipilimumab for the treatment of post-chemotherapy metastatic castration-resistant prostate cancer (mCRPC): Additional results from the randomized phase 2 CheckMate 650 trial","volume":"41","author":"Sharma","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_112","unstructured":"Tsimberidou, A.M., Drakaki, A., Khalil, D.N., Okrah, K., Schachter, M., Gautam, S., Da Silva, D.M., Alayli, F.A., Spencer, C.N., and Foo, W.C. (2024, January 5\u201310). Evaluating nivolumab (nivo) plus ipilimumab (ipi) in patients with metastatic castration-resistant prostate cancer (mCRPC): Clinical and translational results from the AMADEUS prostate expansion cohort. Proceedings of the American Association for Cancer Research Annual Meeting 2024, San Diego, CA, USA."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"S953","DOI":"10.1016\/j.annonc.2023.09.2715","article-title":"1765O Interim results from a phase I study of AMG 509 (xaluritamig), a STEAP1 x CD3 XmAb 2+1 immune therapy, in patients with metastatic castration-resistant prostate cancer (mCRPC)","volume":"34","author":"Kelly","year":"2023","journal-title":"Ann. Oncol."}],"container-title":["Biomolecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2218-273X\/15\/6\/751\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T17:38:08Z","timestamp":1760031488000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2218-273X\/15\/6\/751"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,22]]},"references-count":113,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2025,6]]}},"alternative-id":["biom15060751"],"URL":"https:\/\/doi.org\/10.3390\/biom15060751","relation":{},"ISSN":["2218-273X"],"issn-type":[{"value":"2218-273X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,22]]}}}